APPLICATIONS PUBLISHED 6 JULY 2005

Nitric oxide and its biomedical significance
The Research Foundation of State University of New York 1549300*

A method for the using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
Oklahoma Medical Research Foundation 1549301*

Gastrointestinal compsns comprising GABA derivatives
Warner-Lambert 1549302*

Inhibiting progressive cognitive impairment
The Mount Sinai School of Medicine of New York University 1549303*

Heterocyclic amides and their use in treating thromboembolic diseases and tumours
Merck Patent 1549304*

Alpha 2B or 2B/2C adrenoreceptor agonists for the treatment of neurodegeneration
Allergan 1545305*

Substituted phenylsulphonamide inhibitors of beta-amyloid production
Wyeth; Arqule 1549306*

Agent for medicamentous treatment of acute and chronic pain
Max-Delbrueck-Centrum fuer Molekulare Medizin 1549307*

An inhibitor of the SHH signalling pathway and a testosterone suppressing agent for the treatment of cancer
Medical Research Council 1549308*

Somatostatin analogue compounds
ChemBridge Research Laboratories 1549309*

Potent inhibitor of HCV serine protease
Boehringer Ingelheim International 1549311*

Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
SuperGen 1549312*

Compsn and antiviral activity activity of substituted azaindoleacetic piperazine derivatives
Bristol-Myers Squibb 1549313*

Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and Parkinson's disease
Allergan 1549314*

Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
Merck 1549315*

Inhibitors of TFG-(beta)
Scios 1549316*

Improved imaging agents comprising barbituric acid derivatives
GE Healthcare 1549317*

Crystal structure of aurora-2-protein and binding proteins thereof
Vertex Pharmaceuticals 1549318*

Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyriomidine ring structure and methods of use
King Pharmaceuticals Research & Development 1549319*

Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
Warner-Lambert 1549320*

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
The Regents of the University of California 1549321*

Lipid A and other carbohydrate ligand analogues
Biomira 1549322*

Conjugates comprising central nervous system active drug
A&D Bioscience 1549323*

Classes of compounds that interact with GPCRS
Alchemia 1549325*

Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin
Laboratoires Innothera 1549326*

Compsn for treating haemorrhoids
Carroll, Gaye 1549327*

Use of a human amniotic membrane compsn for prophylaxis and treatment of diseases and conditions of the eye and skin
Ghinelli, Emiliano 1549328*

Extract with anti-tumour and anti-poisonous activity
Unibioscreen 1549329*

Pomolic acid, its isomers, derivatives and their uses, pharmaceutical compsn and method for treating multidrug resistant tumours
Universidade Federal do Rio de Janeiro 1549330*

Use of purslane to treat facial wrinkles
Avon Products 1549331*

Modified asialo-inteferons and uses thereof
The General Hospital Corp 1549332*

Compstatin analogues with improved activity
The Trustees of the University of Pennsylvania 1549333*

A pharmaceutical compsn comprising a retro-iverso isomer peptide
Mok, Kenneth Hun 1549334*

A method of modulating activity and molecules for use therein
Monash University; The University of Melbourne 1549335*

Prevention and/or treatment of inflammatory bowel disease using PYY or agonists thereof
Amylin Pharmaceuticals 1549336*

Glycosaminoglycan-DNAse combination therapy
University of Southampton 1549337*

Biofunctional CPG or oligo-polynucleotide or toxin or enterotoxin containing compsn
Duotol 1549340*

Isolation of immunoglobulin molecules that lack inter-heavy chain disulphide bonds
GTC Therapeutics 1549342*

Pharmaceutical compsns cted to ERB-B1 receptors
Merck Patent 1549344*

Associated between a PPAR ligand and an antioxidant agent and use thereof for treating obesity
Les Laboratoires Servier; Centre National de la Recherche Scientifique 1549348*

Pharmaceutically active oligosaccharide conjugates
Fresenius Kabi Deutschland 1549350*